Facebook-f Linkedin-in

Case Studies

Introduction

Treehill Partners has a long and deep history of achievements for companies in the life science and biopharma sectors.

In this series, we outline a set of case studies that showcase how Treehill was able to achieve specific advantages for product developers, operators and investors, and how we managed to deliver what our clients
required to be able to successfully grow operations and enhance or expedite therapeutic development.

Doctor in an office pointing at a monitor screen showing oncology detection results.
China to US
Newco
Oncology
Public
US market entry

Unlocking global potential for Chinese oncology asset

A multinational biopharmaceutical developer headquartered in China engaged Treehill Partners to provide strategic expertise on an oncology asset it had advanced to Phase II clinical results.
Read Full Story
Scientist in a laboratory examining DNA samples under a microscope during research
US market entry
CGT
Cell & gene therapy
Public
Early-stage clinical

U.S. market entry for Japanese cell therapy specialist

A Japanese-listed developer of cell and gene therapies (CGT) faced challenges progressing beyond domestic Phase I clinical trials.
Read Full Story
Close-up of U.S. and China flags symbolizing bilateral relations and geopolitical tension.
China to US
US market entry
CNS
Private
Clinical stage

China private CNS developer seeking to enter U.S. market

The company engaged Treehill to expand partnerships and further develop long-term development strategies.
Read Full Story
Stock market graph showing financial trends and market performance over time.
Korea
First in human
Oncology
Publicly listed
Success

APAC listed biotech with follow-on asset ready for clinical studies

The biotech was pursuing a mission to develop therapeutics that overcome cancer resistance mechanisms to already established standard treatments.
Read Full Story
Biotech stocks performance chart showing market trends
Korea
Clinical Stage
Oncology
Publicly listed

Asian listed biotech with mid-stage oncology data requiring a transaction

An Asian listed biotech with a phase 2 oncology asset being developed in various combinations with different multinational corporations.
Read Full Story
Asian scientist conducting research and representing advancements in science and technology in Asia.
Europe
Clinical Stage
Oncology
Private
Financing

Private European biotech with mid-stage clinical oncology asset requiring funding

Treehill was engaged by a European private biotech in phase 2 studies of its oncology asset, having almost depleted $60 million in financing.
Read Full Story
Embryo assessment through preimplantation genetic screening to identify chromosomal abnormalities before IVF implantation
US
NewCo
Immuno-oncology
Public
Financing

US listed immune-oncology with technology platform revealing un-financed opportunities

A US-based publicly-listed biotech specialising in immuno-oncology. The company had developed a wide and versatile platform.
Read Full Story
Ophthalmologist examining a patient’s eye during a clinical eye health evaluation.
Ophthalmology
Product relaunch
Medtech
AMD
NewCo
Europe

UK ophthalmology specialist with depleted resources following initial launch during COVID-19 outbreak

Innovative surgical solution to overcome the impact from damage created by Age-related Macular Degeneration.
Read Full Story
Biotech facility showcasing an antimicrobial platform used for developing next-generation anti-infective solutions.
US-based
Fertility
Proof-of-concept
Platform
NewCo

Promising diagnostic platform housed in biotech with focus in other areas

A fertility diagnostic technology platform based in the US engaged Treehill.
Read Full Story
Digital map illustrating China-to-US connections and business opportunities across regions.
China
Financing
Oncology
Pivotal stage
NewCo

Redesigned development plan for Chinese biotech with oncology asset to be in pole-position for first-to-market

A Chinese-based biotech was at the pivotal-stage of development of an asset targeting oncology.
Read Full Story

Stay Up to Date

Thank You

Please choose your subscriptions:

Unsubscribe any time using the footer of our emails. For information about our privacy practices, please visit our privacy policy.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

GET IN CONTACT